[go: up one dir, main page]

RU94046380A - Сульфатная соль замещенного триазола, способ ее получения, фармацевтические композиции на ее основе и способы их получения, способ профилактики и лечения - Google Patents

Сульфатная соль замещенного триазола, способ ее получения, фармацевтические композиции на ее основе и способы их получения, способ профилактики и лечения

Info

Publication number
RU94046380A
RU94046380A RU94046380/04A RU94046380A RU94046380A RU 94046380 A RU94046380 A RU 94046380A RU 94046380/04 A RU94046380/04 A RU 94046380/04A RU 94046380 A RU94046380 A RU 94046380A RU 94046380 A RU94046380 A RU 94046380A
Authority
RU
Russia
Prior art keywords
production
treatment
prophylaxis
base
pharmaceutical compositions
Prior art date
Application number
RU94046380/04A
Other languages
English (en)
Other versions
RU2130022C1 (ru
Inventor
Бейкер Раймонд
Gb]
Гилио Матасса Виктор
Олив Кароль
Джордж Питт Кендал
Эдвард Стори Дэвид
Fr]
Джозеф Стрит Лесли
Ричард Гиблин Александр
Original Assignee
Мерк Шарп энд Дом Лимитед (GB)
Мерк Шарп энд Дом Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211903A external-priority patent/GB9211903D0/en
Priority claimed from GB939307306A external-priority patent/GB9307306D0/en
Application filed by Мерк Шарп энд Дом Лимитед (GB), Мерк Шарп энд Дом Лимитед filed Critical Мерк Шарп энд Дом Лимитед (GB)
Publication of RU94046380A publication Critical patent/RU94046380A/ru
Application granted granted Critical
Publication of RU2130022C1 publication Critical patent/RU2130022C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Сульфат (соль) N,N-диметил-2[5- (1,2,4-триазол-1-илметил)-1P-индол-3-ил] этиламина является селективным агонистом 5-HT-подобных рецепторов и, следовательно, полезна в лечении клинических состояний, особенно мигрени и связанных с ней расстройств, для которых показано применение селективного агониста этих рецепторов.

Claims (1)

  1. Сульфат (соль) N,N-диметил-2[5- (1,2,4-триазол-1-илметил)-1P-индол-3-ил] этиламина является селективным агонистом 5-HT1-подобных рецепторов и, следовательно, полезна в лечении клинических состояний, особенно мигрени и связанных с ней расстройств, для которых показано применение селективного агониста этих рецепторов.
RU94046380/04A 1992-06-05 1993-05-28 N,n-диметил-2-[5-(1,2,4-триазол-1-илметил)-1н-индол-3-ил] этиламина сульфатная соль (2:1) и ее фармацевтически приемлемые гидраты, способы ее получения, фармацевтическая композиция на ее основе, способ ее получения и лекарственное средство RU2130022C1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9211903.1 1992-06-05
GB929211903A GB9211903D0 (en) 1992-06-05 1992-06-05 Pharmaceutical composition
GB939307306A GB9307306D0 (en) 1993-04-07 1993-04-07 Therapeutic agents
GB9307306.2 1993-04-07
PCT/GB1993/001132 WO1993025547A1 (en) 1992-06-05 1993-05-28 The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy

Publications (2)

Publication Number Publication Date
RU94046380A true RU94046380A (ru) 1996-12-10
RU2130022C1 RU2130022C1 (ru) 1999-05-10

Family

ID=26301005

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94046380/04A RU2130022C1 (ru) 1992-06-05 1993-05-28 N,n-диметил-2-[5-(1,2,4-триазол-1-илметил)-1н-индол-3-ил] этиламина сульфатная соль (2:1) и ее фармацевтически приемлемые гидраты, способы ее получения, фармацевтическая композиция на ее основе, способ ее получения и лекарственное средство

Country Status (27)

Country Link
US (1) US5527817A (ru)
EP (1) EP0573221B1 (ru)
JP (2) JP2619197B2 (ru)
KR (1) KR100286411B1 (ru)
CN (1) CN1043532C (ru)
AT (1) ATE165602T1 (ru)
AU (2) AU659311B2 (ru)
BG (1) BG61976B1 (ru)
CA (1) CA2097208C (ru)
CZ (1) CZ282060B6 (ru)
DE (1) DE69318212T2 (ru)
DK (1) DK0573221T3 (ru)
ES (1) ES2116411T3 (ru)
FI (3) FI106201B (ru)
HK (1) HK1010050A1 (ru)
HU (1) HUT71403A (ru)
IL (1) IL105847A (ru)
LV (1) LV12210B (ru)
MX (1) MX9303373A (ru)
NO (1) NO307420B1 (ru)
NZ (1) NZ253210A (ru)
RO (1) RO114326B1 (ru)
RU (1) RU2130022C1 (ru)
SG (1) SG50406A1 (ru)
SK (1) SK279211B6 (ru)
UA (1) UA27908C2 (ru)
WO (1) WO1993025547A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ282060B6 (cs) * 1992-06-05 1997-05-14 Merck Sharp And Dohme Limited Sulfátová sůl substituovaného triazolu, způsob její výroby, farmaceutický prostředek s jejím obsahem a způsob jeho výroby
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
WO1997003068A1 (en) * 1995-07-11 1997-01-30 Merck & Co., Inc. A triazolylmethyl-indole ethylamine bisulfate salt
US6192882B1 (en) * 1997-02-24 2001-02-27 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
US6349719B2 (en) 1997-02-24 2002-02-26 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
JP2002528498A (ja) * 1998-11-02 2002-09-03 メルク エンド カムパニー インコーポレーテッド 片頭痛の治療方法及び医薬組成物
EP2332934B1 (en) 2001-08-15 2017-03-01 Pharmacia & Upjohn Company LLC Processes for the preparation of crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide.
WO2006137083A1 (en) * 2005-06-20 2006-12-28 Natco Pharma Limited Improved process for the preparation of rizatriptan benzoate
ES2270717B1 (es) * 2005-08-08 2008-03-01 Ragactives, S.L. Procedimiento para la obtencion de derivados de triptamina.
WO2007054979A1 (en) * 2005-11-14 2007-05-18 Matrix Laboratories Ltd Process for the large scale production of rizatriptan benzoate
CA2688463A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Process for the preparation of rizatriptan
WO2017130141A1 (en) 2016-01-27 2017-08-03 Instar Technologies A.S. Oromucosal nanofiber carriers for therapeutic treatment
WO2024144413A1 (ru) * 2022-12-28 2024-07-04 Общество С Ограниченной Ответственностью "Ферринг Продакшн" Жидкая фармацевтическая композиция для назального введения, содержащая ризатриптан

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1528319A3 (ru) * 1985-07-23 1989-12-07 Глэксо Груп Лимитед (Фирма) Способ получени производных имидазола или их физиологически приемлемых солей
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
KR920011020B1 (ko) * 1989-07-03 1992-12-26 요시또미세이야꾸 가부시끼가이샤 벤즈아진 화합물 및 그의 의약용도
US5075313A (en) * 1990-09-13 1991-12-24 Eli Lilly And Company 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
GB9026998D0 (en) * 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
CZ283018B6 (cs) * 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
CZ282060B6 (cs) * 1992-06-05 1997-05-14 Merck Sharp And Dohme Limited Sulfátová sůl substituovaného triazolu, způsob její výroby, farmaceutický prostředek s jejím obsahem a způsob jeho výroby

Also Published As

Publication number Publication date
UA27908C2 (uk) 2000-10-16
NO944656D0 (no) 1994-12-02
CZ304494A3 (en) 1995-09-13
RO114326B1 (ro) 1999-03-30
FI20001776A7 (fi) 2000-08-10
US5527817A (en) 1996-06-18
LV12210B (en) 1999-03-20
SK147994A3 (en) 1995-07-11
AU4337293A (en) 1994-01-04
BG99132A (bg) 1995-07-28
JP2972150B2 (ja) 1999-11-08
KR100286411B1 (ko) 2001-04-16
BG61976B1 (bg) 1998-11-30
SG50406A1 (en) 1998-07-20
CN1089263A (zh) 1994-07-13
JPH09176155A (ja) 1997-07-08
RU2130022C1 (ru) 1999-05-10
ES2116411T3 (es) 1998-07-16
FI20001777A7 (fi) 2000-08-10
NZ253210A (en) 1995-09-26
EP0573221B1 (en) 1998-04-29
HK1010050A1 (en) 1999-06-11
IL105847A0 (en) 1993-09-22
LV12210A (lv) 1999-01-20
HU9403478D0 (en) 1995-02-28
KR950701922A (ko) 1995-05-17
NO944656L (no) 1994-12-02
DK0573221T3 (da) 1998-10-07
CA2097208A1 (en) 1993-12-06
MX9303373A (es) 1995-01-31
DE69318212D1 (de) 1998-06-04
AU3987593A (en) 1993-12-09
SK279211B6 (sk) 1998-08-05
FI945694A0 (fi) 1994-12-02
WO1993025547A1 (en) 1993-12-23
CZ282060B6 (cs) 1997-05-14
NO307420B1 (no) 2000-04-03
DE69318212T2 (de) 1998-11-19
EP0573221A1 (en) 1993-12-08
FI106201B (fi) 2000-12-15
FI20001776L (fi) 2000-08-10
AU659311B2 (en) 1995-05-11
FI20001777L (fi) 2000-08-10
HUT71403A (en) 1995-11-28
JPH0641121A (ja) 1994-02-15
CN1043532C (zh) 1999-06-02
JP2619197B2 (ja) 1997-06-11
FI945694L (fi) 1994-12-02
CA2097208C (en) 2005-02-08
IL105847A (en) 1998-09-24
ATE165602T1 (de) 1998-05-15

Similar Documents

Publication Publication Date Title
IL96891A0 (en) Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
RU94046380A (ru) Сульфатная соль замещенного триазола, способ ее получения, фармацевтические композиции на ее основе и способы их получения, способ профилактики и лечения
EA199700251A1 (ru) 5-замещенные-3-(1,2,3,6-тетрагидропиридин-4-ил)- и 3-(пиперидин-4-ил)-1н-индолы и их фармацевтически приемлемые соли и сольваты, фармацевтическая композиция на их основе, способ активации рецепторов 5-нти способ ингибирования нейронной белковой транссудации
EP0354777A3 (en) 3-(4-piperidine)-5-(2-sulfonylaminoethyl) indole derivatives
MY109954A (en) Indole derivatives.
BG101110A (bg) Заместени пиримидинови съединения и тяхното използване
CA2367666A1 (en) Method of treating eating disorders
PT804252E (pt) Agentes queladores metalicos que contem monoaminas diamidas e tiois
HK86793A (en) Indole derivatives
CA2340999A1 (en) 5-arylindole derivatives
HUT61543A (en) Process for producing serotonin antagonist indole derivatives and pharmaceutical compositions comprising same as active ingredient
ES2008360A6 (es) Un procedimiento para la preparacion de cetonas triciclicas.
NO943762L (no) Indolderivater som 5-HT 1 agonister
NO944578L (no) Eksitatoriske aminosyre reseptor antagonister
UA34416C2 (ru) Производные хромана, активные по отношению к 5-нт рецептору, способ их получения и промежуточные соединения
RU94045902A (ru) Производные ациламиноиндола в качестве 5-hti агонистов, фармацевтическая композиция и способ лечения
RU94036749A (ru) Замещенные 1-нафтилпиразол-3-карбоксамиды, способ их получения, содержащие их фармацевтические композиции и промежуточные соединения синтеза
IL106445A0 (en) 4-substituted 1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them
CA2185599A1 (en) Methods for the manufacture of terbinafine, trans-n-methyl-n-(1-naphthylmethyl)-6,6-dimethylhept-2-en-4 -ynyl-1-amine and pharmaceutically acceptable salt thereof, intermediates useful in the manufacture thereof, novel n-methyl-n-(1-naphthylmethyl)-6,6-dimethyl-2-hydroxyheptan- 4-ynyl-1-amine as potential antimycotic agents
EP0635014A1 (en) INDOL DERIVATIVES AS "5-HT1-LIKE" AGONISTS.
CA2275686A1 (en) Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
PT91203A (pt) Processo para a preparacao de novos derivados de antibioticos bu-3608 e de composicoes farmaceuticas que os contem
RU95107655A (ru) Глюкопиранозидбензотиофены, способ получения, фармацевтическая композиция
AU4931590A (en) Indole derivatives
MY110795A (en) The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20040529